Abstract
IntroductionTo evaluate real life experience on the effect of Belimumab in patients with active systemic lupus erythematosus.Case presentationTwenty patinets with musclesketal symptoms were evaluated, three were discontinued for different resons and seventeen completed eight injections of Belimumab during a six month period. A fatigue score was also evaluated at the same time.Discussion and EvaluationMarked reduction of disease activity and fatigue score were observed in the patient group.ConclusionsBelimumab is a novel form of therapy in patients with active systemic lupus erythematosus to be added in the standard of care particularly in patients with skin and joint symptoms.
Highlights
To evaluate real life experience on the effect of Belimumab in patients with active systemic lupus erythematosus.Case presentation: Twenty patinets with musclesketal symptoms were evaluated, three were discontinued for different resons and seventeen completed eight injections of Belimumab during a six month period
Belimumab is a novel form of therapy in patients with active systemic lupus erythematosus to be added in the standard of care in patients with skin and joint symptoms
Belimumab is a human monoclonal antibody that inhibits the cytokine B cell activating factor known as BAFF or BLYS and is to some extent responsible for the the increased autoantibody production observed in patients with systemic lupus erythematosus (SLE). (Zhang et al 2001; Petri et al 2008)
Summary
To evaluate real life experience on the effect of Belimumab in patients with active systemic lupus erythematosus.Case presentation: Twenty patinets with musclesketal symptoms were evaluated, three were discontinued for different resons and seventeen completed eight injections of Belimumab during a six month period. To evaluate real life experience on the effect of Belimumab in patients with active systemic lupus erythematosus. Belimumab (trade name Benlysta) is a human monoclonal antibody that inhibits the cytokine B cell activating factor known as BAFF or BLYS and is to some extent responsible for the the increased autoantibody production observed in patients with systemic lupus erythematosus (SLE). (Zhang et al 2001; Petri et al 2008) It is approved for the treatment of SLE clinical trials did not evaluate more severe disease such as severe lupus nephritis and central nervous manifestations (Furie et al 2011). Corticosteroid daily dose were recorded before during the study and after six months
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
